The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,717,845 in first-year total cost, median $3,358,923.
Most frequent study sections
- Special Emphasis Panel[ZNS1 SRB-G (23)]1
- Special Emphasis Panel[ZNS1 SRB-G (34)]1
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL1
- UNIVERSITY OF UTAH1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease1U01NS120901-01 | CLARDY, STACEY LYNN | UNIVERSITY OF UTAH, UT | $4,005,841 | ZNS1 |
| 2019 | A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson's Disease1U01NS114001-01 | VIDENOVIC, ALEKSANDAR | MASSACHUSETTS GENERAL HOSPITAL, MA | $2,712,004 | ZNS1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.